RTW vs. WTAN, BRW, WWH, SNN, ATT, BHMU, JTC, PIN, FGT, and N91
Should you be buying RTW Biotech Opportunities stock or one of its competitors? The main competitors of RTW Biotech Opportunities include Witan Investment Trust (WTAN), Brewin Dolphin (BRW), Worldwide Healthcare (WWH), Sanne Group (SNN), Allianz Technology Trust (ATT), BH Macro USD (BHMU), JTC (JTC), Pantheon International (PIN), Finsbury Growth & Income (FGT), and Ninety One Group (N91). These companies are all part of the "asset management" industry.
RTW Biotech Opportunities vs.
RTW Biotech Opportunities (LON:RTW) and Witan Investment Trust (LON:WTAN) are both small-cap financial services companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, community ranking, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.
RTW Biotech Opportunities has higher revenue and earnings than Witan Investment Trust. Witan Investment Trust is trading at a lower price-to-earnings ratio than RTW Biotech Opportunities, indicating that it is currently the more affordable of the two stocks.
In the previous week, RTW Biotech Opportunities had 1 more articles in the media than Witan Investment Trust. MarketBeat recorded 1 mentions for RTW Biotech Opportunities and 0 mentions for Witan Investment Trust. RTW Biotech Opportunities' average media sentiment score of 0.91 beat Witan Investment Trust's score of 0.00 indicating that RTW Biotech Opportunities is being referred to more favorably in the media.
3.9% of RTW Biotech Opportunities shares are owned by institutional investors. Comparatively, 8.5% of Witan Investment Trust shares are owned by institutional investors. 16.2% of RTW Biotech Opportunities shares are owned by insiders. Comparatively, 8.2% of Witan Investment Trust shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Witan Investment Trust received 93 more outperform votes than RTW Biotech Opportunities when rated by MarketBeat users. However, 100.00% of users gave RTW Biotech Opportunities an outperform vote while only 67.63% of users gave Witan Investment Trust an outperform vote.
RTW Biotech Opportunities has a net margin of 664.38% compared to Witan Investment Trust's net margin of 89.43%. RTW Biotech Opportunities' return on equity of 25.18% beat Witan Investment Trust's return on equity.
RTW Biotech Opportunities has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Witan Investment Trust has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.
Summary
RTW Biotech Opportunities beats Witan Investment Trust on 9 of the 14 factors compared between the two stocks.
Get RTW Biotech Opportunities News Delivered to You Automatically
Sign up to receive the latest news and ratings for RTW and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RTW Biotech Opportunities Competitors List
Related Companies and Tools
This page (LON:RTW) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy RTW Stock Free RTW Stock Alerts